Long-term outcomes of hydrodynamic ultra-thin strut sirolimus-eluting stent with fluoropolymer containing triflusal: VE LAZQUEZ-EPIC26 study

Background: A new-generation coronary sirolimus eluting-stent(SES), whose novel characteristics are summarized in ultra-thin oval-shaped hydrodynamic struts (68 mu m) and abluminal drug release with permanent fluoropolymer containing the platelet aggregation inhibitor triflusal, showed low target le...

Descripción completa

Detalles Bibliográficos
Autores: Linares Vicente JA, Sainz Laso F, Casanova Sandoval JM, Rumoroso Cueva JR, Gómez Menchero A, Gómez Hospital JA, Pérez Guerrero A, Santos Martinez S, Fernández Portalés J, Romani S, García Del Blanco B, Ocaranza Sánchez R, Urbano Carrillo C, García San Roman K, Vinhas H, Cid Álvarez B, Sanchís Fores J, Tellería Arrieta M, Torres Bosco A, Pinar Bermúdez E, Méndez Castro JJ, Lozano Ruiz de Poveda F, Pérez de Prado A, De la Torre Hernández JM
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2026
País:España
Institución:INCLIVA
Repositorio:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:oai:incliva.fundanetsuite.com:p20264
Acceso en línea:https://incliva.portalinvestigacion.com/publicaciones/20264
Access Level:acceso abierto
Palabra clave:Coronary artery disease
Percutaneous coronary intervention
Drug-eluting stents
Target lesion failure
Stent thrombosis
id ES_f5180cd6ee99f0a2d7cb34d43be209ff
oai_identifier_str oai:incliva.fundanetsuite.com:p20264
network_acronym_str ES
network_name_str España
repository_id_str
spelling Long-term outcomes of hydrodynamic ultra-thin strut sirolimus-eluting stent with fluoropolymer containing triflusal: VE LAZQUEZ-EPIC26 studyLinares Vicente JASainz Laso FCasanova Sandoval JMRumoroso Cueva JRGómez Menchero AGómez Hospital JAPérez Guerrero ASantos Martinez SFernández Portalés JRomani SGarcía Del Blanco BOcaranza Sánchez RUrbano Carrillo CGarcía San Roman KVinhas HCid Álvarez BSanchís Fores JTellería Arrieta MTorres Bosco APinar Bermúdez EMéndez Castro JJLozano Ruiz de Poveda FPérez de Prado ADe la Torre Hernández JMCoronary artery diseasePercutaneous coronary interventionDrug-eluting stentsTarget lesion failureStent thrombosisBackground: A new-generation coronary sirolimus eluting-stent(SES), whose novel characteristics are summarized in ultra-thin oval-shaped hydrodynamic struts (68 mu m) and abluminal drug release with permanent fluoropolymer containing the platelet aggregation inhibitor triflusal, showed low target lesion failure(TLF) and absence of stent thrombosis(ST) at 1 year in a first-in-human study. Long-term clinical efficacy is unknown. We aim to investigate lo ng-term clinical efficacy of this new SES in a real-world population undergoing PCI for native coronary artery. Methods: VELAZQUEZ-EPIC26 is a prospective, observational and multicentre study of a large cohort undergoing PCI with the new SES (ihtDEStinyTM). Primary endpoint was TLF at 2 years (composite of cardiovascular death, target vessel myocardial infarction, or clinically driven target lesion revascularization). Secondary clinical safety and efficacy endpoints included definitive or probable ST, target vessel failure (TVF), major adverse cardiac events (MACE), and BARC 3-5 bleeding. Results: Between 2021 and 2023, 406 patients (mean age 65 +/- 11 years, 75 % males, 26 % diabetes) were included. 519 SES were implanted over 482 target lesions. Mean stent diameter and length were 3.03 +/- 0.49 mm and 22 +/- 7,6 mm respectively. Procedural success rate was 97.3 %. TLF at 2 years was 2,2 % (n = 9). There were 3 cardiovas-cular deaths (0,7 %), none related to SES complications. 1 very late definite stent thrombosis was reported (0,2 %, n = 1). TVF, MACE and BARC 3-5 bleeding rates at years were 3 % (n = 12), 3,2 % (n = 13) and 3,5% (n = 14) respec-tively. Conclusions: Ina large real-world population undergoing PCI for native coronary artery, anew hydrodynamic ultra-thin strut SES with abluminal permanent fluoropolymer containing triflusal shows low TLF and very low ST rates at 2 years.ELSEVIER INC2026info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://incliva.portalinvestigacion.com/publicaciones/20264Cardiovascular Revascularization MedicineISSN: 15538389ISSNe: 18780938reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVAinstname:INCLIVAInglésinfo:eu-repo/semantics/openAccessoai:incliva.fundanetsuite.com:p202642026-06-07T16:35:31Z
dc.title.none.fl_str_mv Long-term outcomes of hydrodynamic ultra-thin strut sirolimus-eluting stent with fluoropolymer containing triflusal: VE LAZQUEZ-EPIC26 study
title Long-term outcomes of hydrodynamic ultra-thin strut sirolimus-eluting stent with fluoropolymer containing triflusal: VE LAZQUEZ-EPIC26 study
spellingShingle Long-term outcomes of hydrodynamic ultra-thin strut sirolimus-eluting stent with fluoropolymer containing triflusal: VE LAZQUEZ-EPIC26 study
Linares Vicente JA
Coronary artery disease
Percutaneous coronary intervention
Drug-eluting stents
Target lesion failure
Stent thrombosis
title_short Long-term outcomes of hydrodynamic ultra-thin strut sirolimus-eluting stent with fluoropolymer containing triflusal: VE LAZQUEZ-EPIC26 study
title_full Long-term outcomes of hydrodynamic ultra-thin strut sirolimus-eluting stent with fluoropolymer containing triflusal: VE LAZQUEZ-EPIC26 study
title_fullStr Long-term outcomes of hydrodynamic ultra-thin strut sirolimus-eluting stent with fluoropolymer containing triflusal: VE LAZQUEZ-EPIC26 study
title_full_unstemmed Long-term outcomes of hydrodynamic ultra-thin strut sirolimus-eluting stent with fluoropolymer containing triflusal: VE LAZQUEZ-EPIC26 study
title_sort Long-term outcomes of hydrodynamic ultra-thin strut sirolimus-eluting stent with fluoropolymer containing triflusal: VE LAZQUEZ-EPIC26 study
dc.creator.none.fl_str_mv Linares Vicente JA
Sainz Laso F
Casanova Sandoval JM
Rumoroso Cueva JR
Gómez Menchero A
Gómez Hospital JA
Pérez Guerrero A
Santos Martinez S
Fernández Portalés J
Romani S
García Del Blanco B
Ocaranza Sánchez R
Urbano Carrillo C
García San Roman K
Vinhas H
Cid Álvarez B
Sanchís Fores J
Tellería Arrieta M
Torres Bosco A
Pinar Bermúdez E
Méndez Castro JJ
Lozano Ruiz de Poveda F
Pérez de Prado A
De la Torre Hernández JM
author Linares Vicente JA
author_facet Linares Vicente JA
Sainz Laso F
Casanova Sandoval JM
Rumoroso Cueva JR
Gómez Menchero A
Gómez Hospital JA
Pérez Guerrero A
Santos Martinez S
Fernández Portalés J
Romani S
García Del Blanco B
Ocaranza Sánchez R
Urbano Carrillo C
García San Roman K
Vinhas H
Cid Álvarez B
Sanchís Fores J
Tellería Arrieta M
Torres Bosco A
Pinar Bermúdez E
Méndez Castro JJ
Lozano Ruiz de Poveda F
Pérez de Prado A
De la Torre Hernández JM
author_role author
author2 Sainz Laso F
Casanova Sandoval JM
Rumoroso Cueva JR
Gómez Menchero A
Gómez Hospital JA
Pérez Guerrero A
Santos Martinez S
Fernández Portalés J
Romani S
García Del Blanco B
Ocaranza Sánchez R
Urbano Carrillo C
García San Roman K
Vinhas H
Cid Álvarez B
Sanchís Fores J
Tellería Arrieta M
Torres Bosco A
Pinar Bermúdez E
Méndez Castro JJ
Lozano Ruiz de Poveda F
Pérez de Prado A
De la Torre Hernández JM
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Coronary artery disease
Percutaneous coronary intervention
Drug-eluting stents
Target lesion failure
Stent thrombosis
topic Coronary artery disease
Percutaneous coronary intervention
Drug-eluting stents
Target lesion failure
Stent thrombosis
description Background: A new-generation coronary sirolimus eluting-stent(SES), whose novel characteristics are summarized in ultra-thin oval-shaped hydrodynamic struts (68 mu m) and abluminal drug release with permanent fluoropolymer containing the platelet aggregation inhibitor triflusal, showed low target lesion failure(TLF) and absence of stent thrombosis(ST) at 1 year in a first-in-human study. Long-term clinical efficacy is unknown. We aim to investigate lo ng-term clinical efficacy of this new SES in a real-world population undergoing PCI for native coronary artery. Methods: VELAZQUEZ-EPIC26 is a prospective, observational and multicentre study of a large cohort undergoing PCI with the new SES (ihtDEStinyTM). Primary endpoint was TLF at 2 years (composite of cardiovascular death, target vessel myocardial infarction, or clinically driven target lesion revascularization). Secondary clinical safety and efficacy endpoints included definitive or probable ST, target vessel failure (TVF), major adverse cardiac events (MACE), and BARC 3-5 bleeding. Results: Between 2021 and 2023, 406 patients (mean age 65 +/- 11 years, 75 % males, 26 % diabetes) were included. 519 SES were implanted over 482 target lesions. Mean stent diameter and length were 3.03 +/- 0.49 mm and 22 +/- 7,6 mm respectively. Procedural success rate was 97.3 %. TLF at 2 years was 2,2 % (n = 9). There were 3 cardiovas-cular deaths (0,7 %), none related to SES complications. 1 very late definite stent thrombosis was reported (0,2 %, n = 1). TVF, MACE and BARC 3-5 bleeding rates at years were 3 % (n = 12), 3,2 % (n = 13) and 3,5% (n = 14) respec-tively. Conclusions: Ina large real-world population undergoing PCI for native coronary artery, anew hydrodynamic ultra-thin strut SES with abluminal permanent fluoropolymer containing triflusal shows low TLF and very low ST rates at 2 years.
publishDate 2026
dc.date.none.fl_str_mv 2026
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://incliva.portalinvestigacion.com/publicaciones/20264
url https://incliva.portalinvestigacion.com/publicaciones/20264
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ELSEVIER INC
publisher.none.fl_str_mv ELSEVIER INC
dc.source.none.fl_str_mv Cardiovascular Revascularization Medicine
ISSN: 15538389
ISSNe: 18780938
reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname:INCLIVA
instname_str INCLIVA
reponame_str r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
collection r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424532273496064
score 15.811543

Similares en LA Referencia